Figure 1.
![Figure 1. Kaplan-Meier survival curves. (A) RAEB patients (N = 336). (B) RAEB patients (N = 336) stratified by type of HMA used (azacitidine [AZA], N = 266 vs decitabine [DEC], N = 70). (C) RAEB patients (N = 336) stratified by those receiving ≥6 cycles (N = 159) or <6 cycles (N = 177) of the HMA.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/131/7/10.1182_blood-2017-10-811729/4/blood811729f1.jpeg?Expires=1736050214&Signature=Of9OkiEVP5SmTN-VleoJJ2SMJF1OcAr-2ODriuF8zGGd8N4w5m2JRQmwZ5L7s1k9euU0itYe8Pj1~GFZE1T3PDeOMfkjbor3~pNJbmcC97SBR7kPg33UYrANwD3QN-Po0Po1lN2Rqicsos87gvcLbHVddClkMlKn4TMFCS55jrg6K1Yn5An1ts1Kp4UGaeVnhKSulHhKBYw5pFQFTf5QoKFkiUyPWqrIk87vEwvIlvrVsgwqmKmgMzNFVFOmS1c2-Xgpn6TneW~NB23NK7qbTzAhi9zAzEVqYGn5d06DE5TuEyNwDwoua9Iol6~aCRhjEHaS~HJHec6WDLfGg-tiqQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Kaplan-Meier survival curves. (A) RAEB patients (N = 336). (B) RAEB patients (N = 336) stratified by type of HMA used (azacitidine [AZA], N = 266 vs decitabine [DEC], N = 70). (C) RAEB patients (N = 336) stratified by those receiving ≥6 cycles (N = 159) or <6 cycles (N = 177) of the HMA.
